Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim

Evaluation of the Efficacy of Management of Patients With Lymphomas Diagnosed at Nimes University Hospital Over 20 Years (1999-2018) Under Real-life Circumstances

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04947618

Acronym

DVR-Lym-Nim

Enrollment

136

Registered

2021-07-01

Start date

2024-01-22

Completion date

2026-06-29

Last updated

2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Malignant

Keywords

Mantle-Cell, Follicular, Hodgkin, T-cell, Primitive Cerebral, Marginal Zone, Waldenström's macroglobulinemia, lymphoma

Brief summary

Observation of a cohort of 400 patients with different types of lymphomas.

Detailed description

A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen. Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results. The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment. The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.

Exclusion criteria

* Patients aged 18 or over who have expressed their desire not to take part in the study. * Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study. * Patients under legal guardianship.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival rate among patients with Hodgkin Lymphomas	2 years after inclusion	The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Mantle-cell Lymphomas	2 years after inclusion	The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Primitive Cerebral Lymphomas	2 years after inclusion	The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Follicular Lymphomas	2 years after inclusion	The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Marginal Zone Lymphomas	2 years after inclusion	The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Overall survival rate among patients with Waldenström's Disease	2 years after inclusion	If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.

Secondary

Measure	Time frame	Description
Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Differences between management of patients with Follicular Lymphomas and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Differences between management of patients with Marginal Zone Lymphomas and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Differences between management of patients with Waldenström's Disease and data described in the literature.	2 years after inclusion	The actual management of these patients will be compared with the data in the literature and any differences will be noted.
Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Reasons for differences between management of patients with Waldenström's Disease actually observed and data described in the literature.	2 years after inclusion	The reasons for any differences noted will be analyzed
Analysis of the efficacy of treatment of patients with Hodgkin Lymphomas.	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Analysis of the efficacy of treatment of patients with Mantle-cell Lymphomas	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Analysis of the efficacy of treatment of patients with Primitive Cerebral Lymphomas	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Analysis of the efficacy of treatment of patients with Follicular Lymphomas	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Analysis of the efficacy of treatment of patients with Marginal Zone Lymphomas	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Analysis of the efficacy of treatment of patients with Waldenström's Disease	2 years after inclusion	The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.

Countries

France

Contacts

STUDY_CHAIRAnissa MEGZARI

CHU de Nîmes (Nîmes University Hospital)

Outcome results